The arrival of a new generation of intraocular lenses and corneal inlays – designed to offer clearer, improved vision without the need for reading glasses – is expected to spur growth in the presbyopia market.

FDA is asking its Ophthalmic Devices Panel to consider the implications of missing data and issues with sizing methodology issues tied to Staar Surgical’s PMA submission for its Visian toric implantable collamer lens to correct myopic astigmatism in adults ages 21 to 45. The panel was scheduled for Feb. 14, but it has been postponed due to weather.

Endo Pharma CEO Dave Holveck is diversifying the company from its core pain franchise into seemingly unrelated fields. Critics argue that he's neglecting its core strengths and acquiring mediocre assets, but he says such moves are necessary to address marketplace shifts.

At this year's meeting of the Congress of the European Society of Cataract and Refractive Surgeons, market leaders made headlines with news of joint ventures in refractive surgery, new product launches and re-launches, and other glimpses into the future of vision correction technology.